PharmD, BCCP |🫀ICU Pharmacist @midamericaheart #ChiefsKingdom
Kansas City, MO
Joined March 2013
- Tweets4K
- Following624
- Followers772
- Likes9.9K
Jack Pluenneke retweeted
⏰ Last chance! PAs & PharmDs who join the ACC by Oct. 31 can receive 3️⃣ months of free membership through 2027 & have their application fee waived with a promo code.
Grow your network, access valuable resources, & more. ➡️ bit.ly/3TIXvH9
#PAsGoBeyond #PharmacistsMonth
ALT This October, the ACC is recognizing the PAs & PharmDs transforming patient care. Join now & save.
Jack Pluenneke retweeted
The @umresfelrx cardiology residency program is recruiting for 1 position for 2027-2028!
Please message me directly if you are interested in attending any of these sessions or would like further information about our program. @accpcardprn #ASHP #PharmacyResidency #Cardiology
Jack Pluenneke retweeted
Unlike parenteral prostacyclins, sotatercept initiation reduces PVR without increasing CI. Different effects on CI may reflect distinct physiological mechanisms or differences in patient characteristics.
🔗: jhltonline.org/article/S1053…
Jack Pluenneke retweeted
Presented today at #LIVES2026:
Among patients with #SepticShock, a hospital-level strategy recommending #Vasopressin initiation at a lower dose threshold of other vasopressors did not reduce 28-day mortality vs a higher threshold strategy. Kidney replacement therapy–free days were also similar, indicating no outcome advantage for the lower-threshold strategy in routine practice.
ja.ma/4B6K4BU
Jack Pluenneke retweeted
Efficacy and Safety of Flecainide Versus Amiodarone for the Cardioversion of paroxysmal Atrial Fibrillation in Patients with Coronary Artery Disease without evidence of residual ischemia: The FLECA-ED Randomized Clinical Trial
heartrhythmjournal.com/artic…
Jack Pluenneke retweeted
We had a great journal club on this yesterday. So, here's my thoughts.
Overall, the trial is uninterpretable & will not change anything I do, & I doubt anything anyone else does. There are numerous fatal flaws. If anything, its utility is a warning how not to design such trials.
do you think the higher recurrence driven by higher recurrence with E. faecalis is noise or potential signal? @BradSpellberg @ABsteward
Jack Pluenneke retweeted
Inspired by @gcfmd, I made a printable 1-page clinic handout to help HF patients create an account at @costplusdrugs . Quadruple therapy for about $30/month including shipping. @HFSA #CardioTwitter
drive.google.com/file/d/1BDi…
Jack Pluenneke retweeted
12/14 Cardiogenic shock mortality has risen nearly fourfold over 25 years, from 1.2 to 4.6 per 100,000.
HF-related shock has now surpassed heart attack–related (AMI) shock as the leading cause in contemporary registries.
#HFSTATS2026
Jack Pluenneke retweeted
9/14 HF costs up to $312B a year in the U.S. today, a figure projected to reach $858B by 2050.
Meanwhile, all four pillars of GDMT for HFrEF are now highly cost-effective, at under $5,000 per QALY with generic pricing.
#HFSTATS2026
Jack Pluenneke retweeted
10/14 ATTR-CM prevalence among Medicare beneficiaries rose more than fivefold from 2010 to 2021, from 15.8 to 85.6 per 100,000.
True prevalence remains unknown because the condition is still underdiagnosed.
#HFSTATS2026
Jack Pluenneke retweeted
What started with an important clinical question evolved into an international collaboration, bringing together colleagues, expertise, and perspectives from across the cardiovascular community.
🔗ahajournals.org/doi/10.1161/…
#Circulation #CardioOncology #CancerAssociatedThrombosis
Jack Pluenneke retweeted
STAGE C2D Definition and Management- Critical Stage with Unmet Need! jacc.org/doi/10.1016/j.jchf.… @ShannonMDunlay @preventfailure @FinnGustafsson @SJGreene_md @lamcardio @akshaydesaimd @MG_Crespo_Leiro @dranulala @TheresaMcDonag3 @colleenkmac @NMHheartdoc @spinneymd @laurentrubymd
Jack Pluenneke retweeted
Another important JACC:HF Position Statement: Defining Clinically Meaningful Within-Patient Changes in HF @AminYehyaMD @hahn_rt @VDelgadoGarcia @noshreza @mpsotka @JJheart_doc @totocarbone @JavedButler1 @NatalieTapaskar @AndrewPAmbrosy jacc.org/doi/epdf/10.1016/j.…
Jack Pluenneke retweeted
🫀 JUST PUBLISHED: HF STATS 2026 is officially here!
We are thrilled to launch the 4th iteration of HF STATS 2026: Heart Failure Epidemiology and Outcomes Statistics, an updated report from the Heart Failure Society of America published in the Journal of Cardiac Failure.
Jack Pluenneke retweeted
The newest episode of #SoCCCPreRounds is live! 🎙️Cardiogenic Shock and High-Risk Pregnancies in the CICU.
Managing cardiogenic shock is challenging enough. Add pregnancy to the equation, and even experienced cardiac intensivists can find themselves navigating unfamiliar territory.
Join host @ElliottMillerMD and @RickyHansra as they discuss for a practical discussion on caring for pregnant patients with cardiogenic shock. Together, they explore the physiologic changes of pregnancy, bedside hemodynamic assessment, medication selection, and the role of multidisciplinary care in achieving the best outcomes for mother and baby.
Listen now: ow.ly/qoKz50ZHWH4
Made possible by unrestricted support from @zoll_cms
#SoCCC #pulmonaryhypertension #CICU
@CCCEnthusiasts @JasonKatzMD @jameshorowitzmd @AnnGageMD @ElliottMillerMD @BalimSenmanMD
Jack Pluenneke retweeted
🫀🫀Pleased to share our latest work on the evolving history of pericarditis published in @CircAHA. Thankful to @AllanLKleinMD1’s mentorship and to my co-authors.
🔗 ahajournals.org/doi/10.1161/…
@AllanLKleinMD1
@HMHCardioFellow
Jack Pluenneke retweeted
We are just getting started
Jack Pluenneke retweeted
Dr. Erika Hellenbart from UIC/UI Health in Chicago shares a testimonial about why she contributes to the Cardiology PRN.
Jack Pluenneke retweeted
🧵..
Think u know ur #aspirin🟡? Think again!😂
Honored to share the design paper for #COATED_AIR,🥇large #RCT of coated vs plain aspirin @ESC_Journals @EditorEHJCVP. 🙏to partner w @psadeghipour @AzitaTalasaz & be supported by a🌟 team. 3000 pts in!✅👇
tinyurl.com/28zxmjzp
Jack Pluenneke retweeted
🌍 The newest TransAtlantic Webinar is available on demand! 🌍 "Anti-Coagulation Strategies in Mechanical Circulatory Support" tackles the balancing act of thrombosis vs. bleeding risk in MCS patients — covering patient- and device-specific considerations, monitoring, and real-world decision-making across temporary and durable platforms.
🎙️ US Faculty: Janhavi Athale, MD (Mayo Clinic) | Case Presenter: Cecily Allen, MD (Johns Hopkins/NIH)
🎙️ European Faculty: Christophe Vandenbriele, MD, PhD (Cardiovascular Center Aalst/OLV) | Case Presenter: Otilia Țica, MD, PhD, MSc (University of Birmingham)
Watch here: youtube.com/watch?v=3aT66m6L…
#SoCCC #ACVC #MechanicalCirculatorySupport #CriticalCareCardiology #Anticoagulation #TransAtlanticWebinar
@ACVCPresident @CCCEnthusiasts @JasonKatzMD @jameshorowitzmd @AnnGageMD @ElliottMillerMD @BalimSenmanMD
